Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 3
3(60.0%)
Phase 1
2(40.0%)
5Total
Phase 3(3)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07553351Phase 3Not Yet Recruiting

GB06 Phase III Trial for Pediatric Growth Hormone Deficiency

Role: lead

NCT07519564Phase 1Not Yet Recruiting

A Phase I Clinical Study to Evaluate the PK, PD, Efficacy, and Safety of GB18 Injection in Patients With Tumor Cachexia

Role: lead

NCT06711523Phase 3Active Not Recruiting

Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy

Role: lead

NCT06277167Phase 1Completed

A Phase I Study in Healthy Participants

Role: lead

NCT06363370Phase 3Recruiting

Human Interferon α1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respiratory Tract Infections

Role: lead

All 5 trials loaded